AI Meets Early Detection: A New Era in Cancer Screening Begins in Mexico

The in vitro diagnostics sector in undergoing a transformative shift, driven by use of artificial intelligence, multi-biomarker analysis, and preventive care strategies. This paradigm shift is more evident in Latin America, where premium institutions like Longevity Medical Institute (LMI) are integrating AI-powered platforms for early-stage cancer screening.

The major challenge in Latin America healthcare sector is access to advanced diagnostic products & services and affordable preventive solutions. Traditional platforms such as Galleri by GRAIL are available in U.S. and often have limited access to other underdeveloped countries owing to cost and infrastructure. The major barriers in Latin America diagnostic sector are as follows:

• Geographical barriers: Patients in rural regions are required to travel long distance for screenings of severe conditions such as cancer.
• Delays: The samples are required to be transported to centralized labs for further interpretation, thereby increasing turnaround time.
• Infrastructure challenges: Limited local lab capacity for complex conditions such as cancer
• Cost: Centralised lab services are expensive owing to logistics and batch processing, along with high turnaround time.

Thus, to overcome such challenges in diagnostic sector, various institutions have collaborated with AI-diagnostics providers to provide actionable screening results. Further, the LMI-Oncoseek model offers comprehensive cancer screening with single blood drop, along with eliminating logistical hurdles and reduces time of the screening results.

“With most of our patients over the age of 50, our collaboration with Oncolnv is strong and strategic fit. Together we’re making advanced U.S. level cancer diagnostics more accessible for people across Mexico.”-Kirk Sanford, CEO and Founder of Longevity Medical Institute

• For instance, in April 2025, Longevity Medical Institute (LMI) collaborated with SeekIn Inc.,for redefining the cancer screening with use of its AI platform OncoSeek with extensive tumor marker panels.

“By combining scientific innovation with clinical practice, our team is advancing preventive cancer care. We are equipping individuals in Mexico with earlier, more accurate diagnostic tools, helping them take timely action when it matters most.”-Jesper Verhey, Director of Oncology

The important parameters of this collaboration are as follows:

• Integration of AI in IVD sector: Use of AI enhances diagnostic precision by analysing protein tumor markers in real time.
• Enhance clinical performance: This platform offers 51.7% sensitivity, 92.9% specificity and overall accuracy of 84.3% in detecting major cancers.
• Expanded cancer coverage: The OncoSeek platform detects nine common cancer types such as breast, colorectal, liver, lung, lymphoma, oesophagus, ovary, pancreas, and stomach cancers.
• Real-world relevance: A single blood drop offers AI analysis and biomarker testing, ensuring patient friendly platform.

“The convenience of single blood sample and rapid reporting has resonated with our patients. Our streamlined workflows enable efficient delivery of comprehensive diagnostic outcomes.”-Edward Ramsay, Director of Clinical Laboratory in Longevity Medical Institute

• Patient centric platform: This platform uses patient centric approach, as single blood drawn offers results from both OncoSeek and LMI’s comprehensive tumour market analysis.
• Local customization: Platform is customized as per the Latin America’s health needs, along with specific diagnostic capabilities available across the world.
• Scientifically backed: The platform is backed and supported by various studies such as Johns Hopkins University School of Medicine.

Strategic Impact on IVD Industry

This collaboration aligns with the global IVD industry, which is propelling towards decentralised, faster turnaround results, and AI-driven preventive models.

• Integration of AI in diagnostics sector
• Localization of high-end diagnostic products to underserved regions
• Streamlined patient flow along with fast turnaround time for complex cancers
• Expanded various cancer types through multi-marker analysis
• Shift from disease treatment approach to early detection and prevention through advanced diagnostic techniques
• Reduced reliance on centralized labs

Thus, this collaboration sets new standards in early cancer screening and focusing on preventive healthcare in Mexico.